Janux Therapeutics, Inc. (JANX)
18.15
+0.33
(+1.85%)
USD |
NASDAQ |
Nov 04, 15:40
Janux Therapeutics Profit Margin (Quarterly) : -214.0% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -214.0% |
| March 31, 2026 | -652.6% |
| December 31, 2025 | |
| September 30, 2025 | -243.1% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | -6.39K% |
| June 30, 2024 | -66.98% |
| March 31, 2024 | -1.18K% |
| December 31, 2023 | -477.8% |
| Date | Value |
|---|---|
| September 30, 2023 | -459.6% |
| June 30, 2023 | -1.66K% |
| March 31, 2023 | -852.5% |
| December 31, 2022 | -564.7% |
| September 30, 2022 | -920.9% |
| June 30, 2022 | -714.1% |
| March 31, 2022 | -843.9% |
| December 31, 2021 | -830.2% |
| September 30, 2021 | -928.9% |
| June 30, 2021 | -1.29K% |
| March 31, 2021 | -601.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -47.64% |
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
| Anika Therapeutics, Inc. | 10.15% |
| BioCryst Pharmaceuticals, Inc. | 35.92% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -10.70% |
| Return on Assets | -10.06% |
| Return on Invested Capital | -10.46% |
| Gross Profit Margin (Quarterly) | 95.49% |
| Operating Margin (Quarterly) | -308.7% |
| Return on Net Operating Assets | -311.6% |